Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

BACKGROUND: About 10% of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study aimed to explore the efficacy and safety of dacomitinib, a second-generation EGFR tyrosine kinase inhibitor (EGFR-TKIs), in treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Xingxiang, Zhou, Yu, Kong, Yi, Chen, Bolin, Yang, Aifang, Li, Jia, Li, Kang, Xu, Yan, Wu, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577935/
https://www.ncbi.nlm.nih.gov/pubmed/37840124
http://dx.doi.org/10.1186/s12885-023-11465-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577935/
https://www.ncbi.nlm.nih.gov/pubmed/37840124
http://dx.doi.org/10.1186/s12885-023-11465-2

Ejemplares similares